Pay vs Performance Disclosure
|
12 Months Ended |
|
Oct. 31, 2024
USD ($)
|
Oct. 31, 2023
USD ($)
|
Oct. 31, 2022
USD ($)
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Pay vs Performance [Table Text Block] |
|
| |
Year |
|
|
$ |
PEO
Total Compensation Amount (1)
|
|
|
$ |
PEO
Actually Paid Compensation Amount (2)
|
|
|
$ |
Non-PEO
NEO Average Total Compensation Amount (1)
|
|
|
$ |
Non-PEO
NEO Average Compensation Actually Paid Amount (2)
|
|
|
$ |
Total
Shareholder Return Amount (3)
|
|
|
$ |
Peer
Group Total Shareholder Return Amount (3)
|
|
|
$ |
Net
Income (Loss) Attributable to Parent (4)
|
|
|
|
Company
Selected Measure Amount (5)
|
|
| |
|
|
Summary
Compensation
|
|
|
Compensation
Actually |
|
|
Average Summary
Compensation
|
|
|
Average Compensation Actually
|
|
|
Value of Initial
Fixed $100
Investment
Based On (3): |
|
|
|
|
|
|
|
| Year |
|
|
Table Total for
PEO (1)
|
|
|
Paid
to
PEO (2)
|
|
|
Table
Total for Non-PEO
NEOs (1)
|
|
|
Paid
to Non-PEO
NEOs (2)
|
|
|
TSR |
|
|
Peer Group
TSR |
|
|
Net Loss
(millions) (4)
|
|
|
Company
Selected
Measure (5)
|
|
| |
2024 |
|
|
$ |
3,476,037 |
|
|
$ |
3,129,297 |
|
|
$ |
1,760,002 |
|
|
$ |
1,493,234 |
|
|
$ |
73.38 |
|
|
$ |
77.75 |
|
|
$ |
12.7 |
|
|
|
-
|
|
| |
2023 |
|
|
$ |
3,639,651 |
|
|
$ |
(2,620,710 |
) |
|
$ |
1,965,876 |
|
|
$ |
134,096 |
|
|
$ |
66.25 |
|
|
$ |
53.07 |
|
|
$ |
9.9 |
|
|
|
- |
|
| |
2022 |
|
|
$ |
2,159,033 |
|
|
$ |
4,767,747 |
|
|
$ |
1,848,558 |
|
|
$ |
3,213,742 |
|
|
$ |
117.40 |
|
|
$ |
65.81 |
|
|
$ |
13.8 |
|
|
|
- |
|
|
|
|
| Named Executive Officers, Footnote [Text Block] |
|
| (1) |
For each fiscal year presented,
Dr. Kumar was our Principal Executive Officer (“PEO”) and Mr. Catelani was our only Non-PEO NEO. |
| (2) |
The CAP amounts presented
reflect the following adjustments to compensation reported within the Summary Compensation Table as required by the SEC: |
| (3) |
Total
Shareholder Return (“TSR”) represents cumulative total shareholder return on a fixed investment of $100 in our common stock
for the period beginning on the last trading day of the fiscal year ended October 31, 2021 through the last trading day of the applicable
fiscal year. Peer Group TSR represents cumulative total shareholder return on a fixed investment of $100 in the S&P Biotechnology
Select Industry Index for the period beginning on the last trading day of the fiscal year ended October 31, 2021 through the last trading
day of the applicable fiscal year. |
| (4) |
The
dollar amounts reported represent the amount of net loss reflected in our audited financial statements for the applicable year. While
we are a pre-revenue biotechnology company and no portion of NEO compensation is dependent upon our net loss, SEC rules require that
net income/loss be presented as a performance measure in this table. |
| (5) |
As a pre-revenue biotechnology company, we have implemented a business model that conserves funds by collaborating with third parties to develop our technologies. As a result, at this stage in our corporate life-cycle, there is no single financial performance measure that our Compensation Committee uses when considering annual compensation for our NEOs. Instead, the Compensation Committee focuses on a variety of factors including the progress of development of our various technologies, our level of operating expenses and our cash position. After discussion with our Compensation Committee, and given the relative weight that the Compensation Committee affords each of these factors and our unique business model, we have elected not to include a “Company-Selected Measure” at this time. We will continue to assess this decision in consultation with our Compensation Committee on a forward looking basis and will include a “Company-Selected Measure” when our Compensation Committee deems it appropriate. |
|
|
|
| PEO Total Compensation Amount |
[1] |
$ 3,476,037
|
$ 3,639,651
|
$ 2,159,033
|
| PEO Actually Paid Compensation Amount |
[2] |
3,129,297
|
(2,620,710)
|
4,767,747
|
| Non-PEO NEO Average Total Compensation Amount |
[1] |
1,760,002
|
1,965,876
|
1,848,558
|
| Non-PEO NEO Average Compensation Actually Paid Amount |
[2] |
$ 1,493,234
|
134,096
|
3,213,742
|
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] |
|
| (2) |
The CAP amounts presented
reflect the following adjustments to compensation reported within the Summary Compensation Table as required by the SEC: |
| |
|
2024 |
|
|
2023 |
|
|
2022 |
|
| Adjustments to Summary Compensation Table amounts to CAP amounts |
|
PEO |
|
|
Average
Non-PEO
NEOs |
|
|
PEO |
|
|
Average
Non-PEO
NEOs |
|
|
PEO |
|
|
Average
Non-PEO
NEOs |
|
| Summary Compensation Table |
|
$ |
3,476,037 |
|
|
$ |
1,760,002 |
|
|
$ |
3,639,651 |
|
|
$ |
1,965,876 |
|
|
$ |
2,159,033 |
|
|
$ |
1,848,558 |
|
| Grant Date FV of option awards granted in fiscal year |
|
|
(2,093,000 |
) |
|
|
(1,046,500 |
) |
|
|
(2,354,100 |
) |
|
|
(1,177,050 |
) |
|
|
(1,088,000 |
) |
|
|
(1,297,600 |
) |
| FV at year-end of outstanding and unvested option awards granted in fiscal year |
|
|
1,104,143 |
|
|
|
552,072 |
|
|
|
1,013,134 |
|
|
|
506,567 |
|
|
|
1,843,723 |
|
|
|
2,229,667 |
|
| Vesting date FV of awards granted in fiscal year and vested in fiscal year |
|
|
385,700 |
|
|
|
192,850 |
|
|
|
510,047 |
|
|
|
255,024 |
|
|
|
358,778 |
|
|
|
424,947 |
|
| Change in FV of awards granted in prior years that are outstanding and unvested as of the end of the fiscal year |
|
|
244,489 |
|
|
|
25,943 |
|
|
|
(4,284,013 |
) |
|
|
(926,354 |
) |
|
|
2,335,311 |
|
|
|
133,389 |
|
| Change in FV of awards granted in prior years and vested in fiscal year |
|
|
11,928 |
|
|
|
8,867 |
|
|
|
(1,145,429 |
) |
|
|
(489,967 |
) |
|
|
(841,098 |
) |
|
|
(125,219 |
) |
| Total Compensation Actually Paid |
|
$ |
3,129,297 |
|
|
$ |
1,493,234 |
|
|
$ |
(2,620,710 |
) |
|
$ |
134,096 |
|
|
$ |
4,767,747 |
|
|
$ |
3,213,742 |
|
|
|
|
| Equity Valuation Assumption Difference, Footnote [Text Block] |
|
| (3) |
Total Shareholder Return
(“TSR”) represents cumulative total shareholder return on a fixed investment of $100 in our common stock for the period
beginning on the last trading day of the fiscal year ended October 31, 2021 through the last trading day of the applicable fiscal
year. Peer Group TSR represents cumulative total shareholder return on a fixed investment of $100 in the S&P Biotechnology Select
Industry Index for the period beginning on the last trading day of the fiscal year ended October 31, 2021 through the last trading
day of the applicable fiscal year. |
|
|
|
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] |
|
Chart
1: Compensation Actually Paid versus TSR
|
|
|
| Compensation Actually Paid vs. Net Income [Text Block] |
|
Chart
2: Compensation Actually Paid versus Net Loss
|
|
|
| Total Shareholder Return Amount |
[3] |
$ 73.38
|
66.25
|
117.40
|
| Peer Group Total Shareholder Return Amount |
[3] |
77.75
|
53.07
|
65.81
|
| Net Income (Loss) Attributable to Parent |
[4] |
$ 12,700,000
|
$ 9,900,000
|
$ 13,800,000
|
| Company Selected Measure Amount |
[5] |
|
|
|
| PEO Name |
|
Dr. Kumar
|
Dr. Kumar
|
Dr. Kumar
|
| Additional 402(v) Disclosure [Text Block] |
|
| (4) |
The dollar amounts reported
represent the amount of net loss reflected in our audited financial statements for the applicable year. While we are a pre-revenue
biotechnology company and no portion of NEO compensation is dependent upon our net loss, SEC rules require that net income/loss be
presented as a performance measure in this table. |
|
|
|
| Grant Date FV of Option Awards Granted in Fiscal Year [Member] | PEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
$ (2,093,000)
|
$ (2,354,100)
|
$ (1,088,000)
|
| Grant Date FV of Option Awards Granted in Fiscal Year [Member] | Non-PEO NEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
(1,046,500)
|
(1,177,050)
|
(1,297,600)
|
| FV at Year-end of Outstanding and Unvested Option Awards Granted in Fiscal Year [Member] | PEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
1,104,143
|
1,013,134
|
1,843,723
|
| FV at Year-end of Outstanding and Unvested Option Awards Granted in Fiscal Year [Member] | Non-PEO NEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
552,072
|
506,567
|
2,229,667
|
| Vesting date FV of Awards Granted in Fiscal Year and Vested in Fiscal Year [Member] | PEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
385,700
|
510,047
|
358,778
|
| Vesting date FV of Awards Granted in Fiscal Year and Vested in Fiscal Year [Member] | Non-PEO NEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
192,850
|
255,024
|
424,947
|
| Change in FV of Awards Granted in Prior Years that are Outstanding and Unvested as of the End of the Fiscal Year [Member] | PEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
244,489
|
(4,284,013)
|
2,335,311
|
| Change in FV of Awards Granted in Prior Years that are Outstanding and Unvested as of the End of the Fiscal Year [Member] | Non-PEO NEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
25,943
|
(926,354)
|
133,389
|
| Change in FV of Awards Granted in Prior Years and Vested in Fiscal Year [Member] | PEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
11,928
|
(1,145,429)
|
(841,098)
|
| Change in FV of Awards Granted in Prior Years and Vested in Fiscal Year [Member] | Non-PEO NEO [Member] |
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
| Adjustment to Compensation Amount |
|
$ 8,867
|
$ (489,967)
|
$ (125,219)
|
|
|